We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Sourcebio International Plc | LSE:SBI | London | Ordinary Share | GB00BKSB1674 | ORD GBP0.0015 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 115.00 | 105.00 | 150.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From May 2022 to May 2024
By Sabela Ojea
SourceBio International PLC said Wednesday that it has resolved its dispute with the U.K.'s tax office on treating the accounting for Covid-19 PCR services as value-added tax exempt.
The U.K. provider of laboratory services said it has received written confirmation from the U.K.'s HM Revenue & Customs on the acceptance of SourceBio's VAT position.
In December 2021, the U.K.'s tax office issued a letter that challenged the group's VAT treatment of PCR testing services provided.
"HMRC suggested that some of those services should have been treated as standard rated for VAT purposes," SourceBio said.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
September 21, 2022 03:29 ET (07:29 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Sourcebio Chart |
1 Month Sourcebio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
